Cargando…

The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial

Background: Tocilizumab and baricitinib are considered standard treatments for hospitalized COVID-19 patients with an inflammatory status. However, the effects of co-administering these medications aiming for more rapid patient recovery are controversial among practitioners. The potential benefits i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dastan, Farzaneh, Jamaati, Hamidreza, Barati, Saghar, Varmazyar, Shahrzad, Yousefian, Sahar, Niknami, Elmira, Tabarsi, Payam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620525/ https://www.ncbi.nlm.nih.gov/pubmed/37927607 http://dx.doi.org/10.3389/fphar.2023.1265541

Ejemplares similares

Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial
por: Tabarsi, Payam, et al.
Publicado: (2021)

Determination of Voriconazole Plasma Concentration by HPLC Technique and Evaluating Its Association with Clinical Outcome and Adverse Effects in Patients with Invasive Aspergillosis
por: Yousefian, Sahar, et al.
Publicado: (2021)

Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial
por: Fakharian, Atefeh, et al.
Publicado: (2021)

Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial
por: Barati, Saghar, et al.
Publicado: (2021)

Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial
por: Malekzadeh, Reza, et al.
Publicado: (2020)

Evaluation of noscapine-licorice combination effects on cough relieving in COVID-19 outpatients: A randomized controlled trial
por: Barati, Saghar, et al.
Publicado: (2023)

Tocilizumab administration in a refractory case of COVID-19
por: Dastan, Farzaneh, et al.
Publicado: (2020)

Tocilizumab as a promising agent against COVID-19: Issues and challenges
por: Dastan, Farzaneh, et al.
Publicado: (2021)

Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab
por: Tabarsi, Payam, et al.
Publicado: (2021)

A Fourteen-day Experience with Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS): An Iranian Treatment Protocol
por: Jamaati, Hamidreza, et al.
Publicado: (2020)

Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial
por: Dastan, Farzaneh, et al.
Publicado: (2020)

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial
por: Karampitsakos, Theodoros, et al.
Publicado: (2023)

Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial
por: Dastan, Farzaneh, et al.
Publicado: (2020)

Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone
por: Wong, Carlos K. H., et al.
Publicado: (2022)

Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis
por: Cherian, Jerin Jose, et al.
Publicado: (2022)

Evaluating the Effect of Acetazolamide on the Prevention of Post-operative Acute Kidney Injury after Coronary Artery Bypass Grafting Surgery: A Randomized, Open-labeled Clinical Trial
por: Afzal, Golnaz, et al.
Publicado: (2021)

Evaluating the Effects of Melatonin on the Oxidative Stress and Duration of Atrial Fibrillation following Coronary Artery Bypass Graft Surgery: A Randomised Controlled Trial
por: Dastan, Farzaneh, et al.
Publicado: (2023)

Successful Management of COVID-19 With Adalimumab in a Post-Coronary Artery Bypass Graft Surgery Patient
por: Fakharian, Atefeh, et al.
Publicado: (2022)

The Efficacy of Tocilizumab in the Treatment of Patients with Refractory Immune-Mediated Necrotizing Myopathies: An Open-Label Pilot Study
por: Li, Sizhao, et al.
Publicado: (2021)

509. A Comparison of Tocilizumab and Baricitinib for Hospitalized Patients with Severe COVID-19
por: Aytoda, Priyanka, et al.
Publicado: (2023)

Real Clinical Practice and Therapeutic Management Following COVID-19 Crisis in two Hospitals in Iran: A Statistical and Conceptual View
por: Najafi, Ali, et al.
Publicado: (2020)

Immunopathogenesis of Pneumonia in COVID-19
por: Alipoor, Shamila D., et al.
Publicado: (2020)

The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review
por: Rezaei, Mitra, et al.
Publicado: (2021)

Study of the Effects of Melatonin on Sleep Disorders in Pulmonary Sarcoidosis Patients
por: Feizabadi, Faezeh, et al.
Publicado: (2023)

Study Protocol on Antimicrobial Stewardship in a Tertiary Respiratory Referral Hospital
por: Jamaati, Hamidreza, et al.
Publicado: (2018)

Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2–adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial
por: Tabarsi, Payam, et al.
Publicado: (2023)

Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19
por: Masiá, Mar, et al.
Publicado: (2021)

Hemoptysis Resolution with Rituximab in Behçet's Disease: A Case Report
por: Jamaati, Hamidreza, et al.
Publicado: (2022)

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study
por: Bryushkova, Ekaterina A., et al.
Publicado: (2022)

Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19
por: Foo, Hong, et al.
Publicado: (2023)

2648. Taming the Cytokine Storm: Baricitinib versus Tocilizumab for COVID-19 Hyperinflammation
por: Radziszewski, Skyler, et al.
Publicado: (2023)

513. Evaluating the safety of baricitinib versus tocilizumab in hospitalized patients with COVID-19
por: Brickel, Kendall, et al.
Publicado: (2023)

Combination therapy of IFNβ1 with lopinavir–ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients
por: Baghaei, Parvaneh, et al.
Publicado: (2021)

Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure
por: Gavriilidis, Efstratios, et al.
Publicado: (2022)

Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort
por: Karolyi, Mario, et al.
Publicado: (2022)

IgM-enriched immunoglobulin in COVID-19: Case series of 15 severely ill SARS-CoV-2-infected patients
por: Tabarsi, Payam, et al.
Publicado: (2021)

NRITLD Protocol for the Management of Outpatient Cases of COVID-19
por: Rezaei, Mitra, et al.
Publicado: (2021)

Efficacy of Early Prone Positioning Combined with Noninvasive Ventilation in COVID-19
por: Hashemian, Seyed Mohammadreza, et al.
Publicado: (2021)

Baricitinib treatment for refractory skin changes in POEMS syndrome: a case report
por: Xie, Jingjing, et al.
Publicado: (2023)

No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial
por: Jamaati, Hamidreza, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oidlgio41dnmtfhrghdkslrhpc